Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.91, $0.15 better than the analyst estimate of $0.76. Revenue for the quarter came in at $231 million versus the consensus estimate of $208.94 million.

GUIDANCE:

Halozyme Therapeutics sees FY2024 EPS of $3.65-$4.05, versus the consensus of $4.72. Halozyme Therapeutics sees FY2024 revenue of $0.93-1.01 billion, versus the consensus of $0.98 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.